As the first cohort of patients are dosed in the Phase II trial, multiple new trial sites are added for the glioblastoma ...
SELLAS has announced positive data from preclinical studies identifying the ASXL1 mutation as a predictor of response to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback